Company news
Clearmind Medicine Inc. (NASDAQ:CMND) news
Every Clearmind Medicine Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled
September 1, 2026
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
August 24, 2026
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint
August 13, 2026
Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Com...
August 11, 2026
Clearmind Medicine Signs Letter of Intent to Acquire 51% Majority Stake in EV Wireless Charging Solutions for Automated Parking Systems C...
August 3, 2026
Clearmind Announces Positive Safety Findings for CMND 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part ...
July 30, 2026
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
July 28, 2026
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar...
July 20, 2026
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
July 17, 2026
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
July 16, 2026
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
July 13, 2026
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery I...
July 10, 2026
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
July 7, 2026
Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
June 29, 2026
Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
June 22, 2026
Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
June 18, 2026
Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
June 16, 2026
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
June 5, 2026
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depressi...
May 29, 2026
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
May 26, 2026
Clearmind Medicine Announces 1-for-10 Reverse Share Split
May 19, 2026
Clearmind Medicine Signs Agreement to Examine MEAI in Combination and Sequencing with Tirzepatide Against Blockbuster GLP-1 Medications
May 18, 2026
Clearmind Medicine CEO Dr. Adi Zuloff-Shani named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.C.
May 15, 2026
Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol...
May 12, 2026
Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial
May 11, 2026
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD
May 5, 2026
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
April 27, 2026
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health...
April 20, 2026
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
April 15, 2026
Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
April 14, 2026
Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Tri...
March 30, 2026
Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
March 27, 2026
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Tri...
March 19, 2026
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
March 17, 2026
NeuroThera Labs - Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
March 16, 2026
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
March 13, 2026
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Target...
March 12, 2026
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Posi...
March 11, 2026
NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight...
March 11, 2026
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 10, 2026
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
March 4, 2026
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
February 19, 2026
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa ...
February 9, 2026
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplasto...
February 6, 2026
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Acc...
February 3, 2026
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
January 20, 2026
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Tria...
January 14, 2026
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 31, 2025
Clearmind Medicine Reflects on a Transformative 2025: Key Clinical Advancements, Expanded Global Reach, and Strengthened Foundation for F...
December 24, 2025
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100
December 16, 2025